Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2005 2
2006 2
2007 4
2008 4
2009 4
2010 6
2011 4
2012 1
2013 2
2015 4
2016 3
2017 4
2018 1
2019 4
2020 5
2021 6
2022 7
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Development of Pandemic Vaccines: ERVEBO Case Study.
Wolf J, Jannat R, Dubey S, Troth S, Onorato MT, Coller BA, Hanson ME, Simon JK. Wolf J, et al. Among authors: dubey s. Vaccines (Basel). 2021 Feb 25;9(3):190. doi: 10.3390/vaccines9030190. Vaccines (Basel). 2021. PMID: 33668698 Free PMC article. Review.
Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
Huttner A, Agnandji ST, Engler O, Hooper JW, Kwilas S, Ricks K, Clements TL, Jonsdottir HR, Nakka SS, Rothenberger S, Kremsner P, Züst R, Medaglini D, Ottenhoff T, Harandi AM, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia. Huttner A, et al. Clin Microbiol Infect. 2023 Dec;29(12):1587-1594. doi: 10.1016/j.cmi.2023.08.026. Epub 2023 Sep 3. Clin Microbiol Infect. 2023. PMID: 37661067
Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates.
Gunn BM, McNamara RP, Wood L, Taylor S, Devadhasan A, Guo W, Das J, Nilsson A, Shurtleff A, Dubey S, Eichberg M, Suscovich TJ, Saphire EO, Lauffenburger D, Coller BA, Simon JK, Alter G. Gunn BM, et al. Among authors: dubey s. Cell Rep. 2023 Apr 25;42(4):112402. doi: 10.1016/j.celrep.2023.112402. Epub 2023 Apr 15. Cell Rep. 2023. PMID: 37061918 Free PMC article.
Preclinical and clinical development of a dengue recombinant subunit vaccine.
Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA. Manoff SB, et al. Among authors: dubey sa. Vaccine. 2015 Dec 10;33(50):7126-34. doi: 10.1016/j.vaccine.2015.09.101. Epub 2015 Oct 14. Vaccine. 2015. PMID: 26458804 Review.
Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines.
Coller BG, Lapps W Jr, Yunus M, Bruno S, Eichberg MJ, Lee AW, Liu K, Drury R, Millogo J, Macareo LR, Armstrong TH, Blue JT, Isopi LA, Hughes M, VanRheenen SM, Deutsch J, Tell JG, Dubey SA. Coller BG, et al. Among authors: dubey sa. Vaccines (Basel). 2022 Sep 1;10(9):1446. doi: 10.3390/vaccines10091446. Vaccines (Basel). 2022. PMID: 36146524 Free PMC article. Review.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Among authors: dubey s. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
66 results